Pulmonary lesion after surgery for renal cancer: progression or new primary?
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05041-x ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Daniele Cignoli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele …. Hauptthemen laut MEDLINE: Kidney Neoplasms, Lung Neoplasms, Carcinoma, Renal Cell, Disease Progression. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To investigate clinical and radiological differences between kidney metastases to the lung (RCCM +) and metachronous lung cancer (LC) detected during follow-up in patients surgically treated for Renal Cell Carcinoma (RCC). METHODS: cM0 surgically-treated RCC who harbored a pulmonary mass during follow-up were retrospectively scrutinized. Univariate logistic regression assessed predictive features for differentiating between LC and RCCM + . Multivariable analyses (MVA) were fitted to predict factors that could influence time between detection and histological diagnosis of the pulmonary mass, and how this interval could impact on survivals. RESULTS: 87% had RCCM + and 13% had LC. LC were more likely to have smoking history (75% vs. 29%, p < 0.001) and less aggressive RCC features (cT1-2: 94% vs. 65%, p = 0.01; pT1-2: 88% vs. 41%, p = 0.02; G1-2: 88% vs. 37%, p < 0.001). The median interval between RCC surgery and lung mass detection was longer between LC (55 months [32.8-107.2] vs. 20 months [9.0-45.0], p = 0.01). RCCM + had a higher likelihood of multiple (3[1-4] vs. 1[1-1], p < 0.001) and bilateral (51% vs. 6%, p = 0.002) pulmonary nodules, whereas LC usually presented with a solitary pulmonary nodule, less than 20 mm. Univariate analyses revealed that smoking history (OR:0.79; 95% CI 0.70-0.89; p < 0.001) and interval between RCC surgery and lung mass detection (OR:0.99; 95% CI 0.97-1.00; p = 0.002) predicted a higher risk of LC. Conversely, size (OR:1.02; 95% CI 1.01-1.04; p = 0.003), clinical stage (OR:1.14; 95% CI 1.06-1.23; p < 0.001), pathological stage (OR:1.14; 95% CI 1.07-1.22; p < 0.001), grade (OR:1.15; 95% CI 1.07-1.23; p < 0.001), presence of necrosis (OR:1.17; 95% CI 1.04-1.32; p = 0.01), and lymphovascular invasion (OR:1.18; 95% CI 1.01-1.37; p = 0.03) of primary RCC predicted a higher risk of RCCM + . Furthermore, number (OR:1.08; 95% CI 1.04-1.12; p < 0.001) and bilaterality (OR:1.23; 95% CI 1.09-1.38; p < 0.001) of pulmonary lesions predicted a higher risk of RCCM + . Survival analysis showed a median second PFS of 10.9 years (95% CI 3.3-not reached) for LC and a 3.8 years (95% CI 3.2-8.4) for RCCM + . The median OS time was 6.5 years (95% CI 4.4-not reached) for LC and 6 years (95% CI 4.3-11.6) for RCCM + . CONCLUSIONS: Smoking history, primary grade and stage of RCC, interval between RCC surgery and lung mass detection, and number of pulmonary lesions appear to be the most valuable predictors for differentiating new primary lung cancer from RCC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. cignoli.daniele@hsr.it.
- Unit of Thoracic Surgery, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
- Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
- Unit of Anatomic Pathology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
- Unit of Medical Oncology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Zitieren
APA
Cignoli, D., Bandiera, A., Rosiello, G., Castorina, R., Re, C., Cei, F., Musso, G., Belladelli, F., Freschi, M., Lucianò, R., Raggi, D., Negri, G., Necchi, A., Salonia, A., Montorsi, F., Larcher, A., & Capitanio, U. (2024). Pulmonary lesion after surgery for renal cancer: progression or new primary?. World Journal of Urology. https://doi.org/10.1007/s00345-024-05041-x
Vancouver
Cignoli D, Bandiera A, Rosiello G, Castorina R, Re C, Cei F, et al. Pulmonary lesion after surgery for renal cancer: progression or new primary?. World Journal of Urology. 2024. doi:10.1007/s00345-024-05041-x
BibTeX
@article{Cignoli2024,
author = {Cignoli, Daniele and Bandiera, Alessandro and Rosiello, Giuseppe and Castorina, Riccardo and Re, Chiara and Cei, Francesco and Musso, Giacomo and Belladelli, Federico and Freschi, Massimo and Lucianò, Roberta and Raggi, Daniele and Negri, Giampiero and Necchi, Andrea and Salonia, Andrea and Montorsi, Francesco and Larcher, Alessandro and Capitanio, Umberto},
title = {Pulmonary lesion after surgery for renal cancer: progression or new primary?},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05041-x}
}
EUVIMED